ERBB signaling in CTCs of ovarian cancer and glioblastoma.

Q2 Biochemistry, Genetics and Molecular Biology Genes and Cancer Pub Date : 2017-11-01 DOI:10.18632/genesandcancer.162
Anjali Geethadevi, Deepak Parashar, Erin Bishop, Sunila Pradeep, Pradeep Chaluvally-Raghavan
{"title":"ERBB signaling in CTCs of ovarian cancer and glioblastoma.","authors":"Anjali Geethadevi,&nbsp;Deepak Parashar,&nbsp;Erin Bishop,&nbsp;Sunila Pradeep,&nbsp;Pradeep Chaluvally-Raghavan","doi":"10.18632/genesandcancer.162","DOIUrl":null,"url":null,"abstract":"<p><p>Circulating Tumor Cells (CTCs) are floating cell populations, which are resistant to anoikis after detachment from the primary sites and travel through the circulatory and lymphatic systems to disseminate throughout the body. CTCs are considered as seed cells for metastasis, and thus isolation of CTCs does not require any invasive procedure. Based on the nature and location of ovarian cancer and glioblastoma, the role of CTCs and hematogenous (carried by blood) spreading of tumor cells in these cancers were not understood well. Dysregulation of epidermal growth factor receptor (EGFR/ERBB) family members due to their overexpression and/or mutation have been known to contribute to the etiology and progression of ovarian cancer and glioblastoma. However, the role of ERBB receptors on CTC formation of ovarian cancer and glioblastoma is not well established. This report highlights the role of ERBB family receptors on resistance to anoikis and CTC formation in ovarian cancer and glioblastoma. Recent research on CTCs demonstrates that capturing ERBB receptor positive cells from circulating system is an efficient approach to isolate CTCs for genomic and proteomic characterization of tumor cells. Therefore, ERBB-targeted isolation of CTCs would help to design therapy to treat cancer, determine drug responses and drug-resistant mechanisms in cancer patients.</p>","PeriodicalId":38987,"journal":{"name":"Genes and Cancer","volume":"8 11-12","pages":"746-751"},"PeriodicalIF":0.0000,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5755720/pdf/","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genes and Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18632/genesandcancer.162","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 16

Abstract

Circulating Tumor Cells (CTCs) are floating cell populations, which are resistant to anoikis after detachment from the primary sites and travel through the circulatory and lymphatic systems to disseminate throughout the body. CTCs are considered as seed cells for metastasis, and thus isolation of CTCs does not require any invasive procedure. Based on the nature and location of ovarian cancer and glioblastoma, the role of CTCs and hematogenous (carried by blood) spreading of tumor cells in these cancers were not understood well. Dysregulation of epidermal growth factor receptor (EGFR/ERBB) family members due to their overexpression and/or mutation have been known to contribute to the etiology and progression of ovarian cancer and glioblastoma. However, the role of ERBB receptors on CTC formation of ovarian cancer and glioblastoma is not well established. This report highlights the role of ERBB family receptors on resistance to anoikis and CTC formation in ovarian cancer and glioblastoma. Recent research on CTCs demonstrates that capturing ERBB receptor positive cells from circulating system is an efficient approach to isolate CTCs for genomic and proteomic characterization of tumor cells. Therefore, ERBB-targeted isolation of CTCs would help to design therapy to treat cancer, determine drug responses and drug-resistant mechanisms in cancer patients.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
卵巢癌和胶质母细胞瘤CTCs中的ERBB信号传导。
循环肿瘤细胞(CTCs)是漂浮的细胞群,它们在脱离原发部位后对肿瘤具有抵抗力,并通过循环系统和淋巴系统传播到全身。ctc被认为是转移的种子细胞,因此分离ctc不需要任何侵入性手术。基于卵巢癌和胶质母细胞瘤的性质和位置,ctc和肿瘤细胞的血液扩散在这些癌症中的作用尚不清楚。由于表皮生长因子受体(EGFR/ERBB)家族成员的过度表达和/或突变而导致的失调已被认为是卵巢癌和胶质母细胞瘤的病因和进展的原因之一。然而,ERBB受体在卵巢癌和胶质母细胞瘤CTC形成中的作用尚不明确。本报告强调了ERBB家族受体在卵巢癌和胶质母细胞瘤中抗肿瘤和CTC形成中的作用。最近对CTCs的研究表明,从循环系统中捕获ERBB受体阳性细胞是分离CTCs用于肿瘤细胞基因组和蛋白质组学表征的有效方法。因此,erbb靶向ctc的分离将有助于设计治疗癌症的疗法,确定癌症患者的药物反应和耐药机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Genes and Cancer
Genes and Cancer Biochemistry, Genetics and Molecular Biology-Genetics
CiteScore
3.90
自引率
0.00%
发文量
6
期刊最新文献
Analysis of pathogenic variants in retinoblastoma reveals a potential gain of function mutation. Dialyl-sulfide with trans-chalcone prevent breast cancer prohibiting SULT1E1 malregulations and oxidant-stress induced HIF1a-MMPs induction. Inhibitory effect of miR-377 on the proliferative and invasive behaviors of prostate cancer cells through the modulation of MYC mRNA via its interaction with BCL-2/Bax, PTEN, and CDK4. Roles of USP1 in Ewing sarcoma. Mechanistically based blood proteomic markers in the TGF-β pathway stratify risk of hepatocellular cancer in patients with cirrhosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1